Top-Rated Dividend StocksTop-Rated DividendNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $28.70 -0.37 (-1.27%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$28.61▼$29.1250-Day Range$25.63▼$29.2752-Week Range$25.20▼$31.66Volume2.74 million shsAverage Volume2.71 million shsMarket Capitalization$17.15 billionP/E Ratio21.42Dividend Yield2.93%Price Target$42.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Royalty Pharma alerts: Email Address Royalty Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside46.3% Upside$42.00 Price TargetShort InterestHealthy3.73% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.86Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth7.92%From $4.04 to $4.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.86 out of 5 starsFinance Sector38th out of 871 stocksPharmaceutical Preparations Industry8th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.73% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 3.97%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.88%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.27% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 3.3 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search InterestOnly 16 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows18 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 157% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to grow by 7.92% in the coming year, from $4.04 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 21.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 21.42, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 31.96.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 4.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.Click here and follow the three simple steps Martin shares in this video to protect your savings whi About Royalty Pharma Stock (NASDAQ:RPRX)Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesSeptember 7 at 3:39 AM | finance.yahoo.comRoyalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?September 4 at 11:27 AM | benzinga.comRare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance CutSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 3, 2024 | globenewswire.comRoyalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementAugust 31, 2024 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Upgraded by StockNews.com to "Buy"August 29, 2024 | finance.yahoo.comRoyalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | globenewswire.comRoyalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | americanbankingnews.comStockNews.com Downgrades Royalty Pharma (NASDAQ:RPRX) to HoldSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 28, 2024 | americanbankingnews.comStockNews.com Lowers Royalty Pharma (NASDAQ:RPRX) to HoldAugust 27, 2024 | 247wallst.comGoldman Sachs Predicts a Double-Digit Rally for These 2 Growth StocksAugust 26, 2024 | finance.yahoo.comJim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’August 23, 2024 | nz.finance.yahoo.comRoyalty Pharma plc (RPD.MU)August 22, 2024 | seekingalpha.comRoyalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy RatingAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Royalty Pharma Amidst Strong Financials and Positive Growth OutlookAugust 11, 2024 | seekingalpha.comDividend Champion, Contender, And Challenger Highlights: Week Of August 11August 11, 2024 | finance.yahoo.comRoyalty Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Royalty Pharma (RPRX), Arcellx Inc (ACLX)See More Headlines Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 6/14 Dividend5/16/2024Dividend Payable6/14/2024Last Earnings8/08/2024Ex-Dividend for 9/13 Dividend8/16/2024Today9/07/2024Dividend Payable9/13/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Stock Price Target$42.00 High Stock Price Target$51.00 Low Stock Price Target$28.00 Potential Upside/Downside+46.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.34 Trailing P/E Ratio21.42 Forward P/E Ratio7.10 P/E Growth4.28Net Income$1.13 billion Net Margins30.08% Pretax Margin46.03% Return on Equity23.61% Return on Assets14.05% Debt Debt-to-Equity Ratio0.78 Current Ratio9.35 Quick Ratio9.35 Sales & Book Value Annual Sales$2.24 billion Price / Sales7.66 Cash Flow$4.51 per share Price / Cash Flow6.36 Book Value$16.88 per share Price / Book1.70Miscellaneous Outstanding Shares597,437,000Free Float484,521,000Market Cap$17.15 billion OptionableOptionable Beta0.46 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman of the Board & CEO Mr. Terrance P. CoyneExecutive VP & CFOMr. George Wingate Lloyd (Age 64)Executive VP of Investments & Chief Legal Officer Comp: $4.56MMr. Christopher Hite (Age 56)Vice Chairman & Executive VP Comp: $4.56MDr. Marshall Jonathan Urist M.D. (Age 48)Ph.D., Executive Vice President of Research & Investments Comp: $4.56MMr. Arthur Richard McGivern J.D.Executive Vice President of Investments & General CounselMr. Ashwin Pai M.D.Executive Vice President of InvestmentsMs. Kristin Stafford (Age 42)Senior VP & Chief Accounting Officer Mr. Eric Cornelius SchneiderSenior VP & Chief Technology OfficerDr. James Folmar Reddoch Ph.D. (Age 54)Executive VP of Investments & Chief Scientific Officer Comp: $3.4MMore ExecutivesKey CompetitorsHorizon Therapeutics PublicNASDAQ:HZNPJazz PharmaceuticalsNASDAQ:JAZZPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 23,178 shares on 9/5/2024Ownership: 0.004%Aurora Investment CounselBought 6,544 shares on 8/22/2024Ownership: 0.008%Truist Financial CorpSold 10,211 shares on 8/21/2024Ownership: 0.002%Susquehanna International Group LLPSold 13,300 shares on 8/16/2024Ownership: 0.000%Regal Investment Advisors LLCBought 3,700 shares on 8/16/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Royalty Pharma plc: Royalty Pharma plc has a consistent track record of paying dividends, providing investors with a steady income stream. The current dividend yield of 2.94% is attractive for income-oriented investors. The company has a strong net margin of 35.70%, indicating efficient cost management and profitability. Analysts have given Royalty Pharma plc a "Moderate Buy" rating with an average price target of $41.80, suggesting potential upside for investors. Despite recent fluctuations, Royalty Pharma's stock price has shown resilience, trading within a narrow range, which may indicate stability. Royalty Pharma plc's involvement in funding innovations in the biopharmaceutical industry can provide exposure to potentially lucrative developments in healthcare. Cons Investors should be bearish about investing in Royalty Pharma plc for these reasons: The company's revenue for the last reported quarter was below analysts' expectations, which may raise concerns about its growth prospects. Royalty Pharma plc's P/E ratio of 21.29 and P/E/G ratio of 3.74 indicate that the stock may be relatively overvalued compared to its growth potential. Market analysts have issued a mix of hold and buy ratings on the stock, suggesting uncertainty about its future performance. The stock's 52-week high of $31.66 is not significantly higher than the current trading price, potentially limiting short-term capital gains for investors. Royalty Pharma plc's beta of 0.46 indicates lower volatility compared to the market average, which may result in slower price movements for traders seeking quick profits. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 20, 2024. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com. RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX shares have increased by 2.2% and is now trading at $28.70. View the best growth stocks for 2024 here. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) announced its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.01. The biopharmaceutical company had revenue of $537 million for the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a net margin of 30.08% and a trailing twelve-month return on equity of 23.61%. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Top institutional shareholders of Royalty Pharma include Baillie Gifford & Co. (2.74%), Swedbank AB (1.81%), New South Capital Management Inc. (0.39%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include 1978 Sicaf Sif SA Gg, 1978 Sicaf Sif SA - Gg St Gg, Mario Germano Giuliani, Avara Management Ltd, Terrance P Coyne, James F Reddoch, Pablo G Legorreta, George W Lloyd, Marshall Urist, Rory B Riggs and Henry A Fernandez. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD) and Netflix (NFLX). This page (NASDAQ:RPRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RPRX Stock Alerts